ACE and heart failure: In HFrEF, the Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure and Aliskiren Trial to Minimize Outcomes in Patients with Heart failure trials, which included a total of 12,058 men and 3,357 women, showed that all-cause mortality was lower in women than in men (adjusted HR: 0.68; 95% CI: 0.62–0.74; P < 0.001) 19.